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Abstract
Background: Limited data are available on the distribution of human papillomavirus (HPV) genotypes in the
general population and in invasive cervical cancer (ICC) in Uganda. Yet, with the advent of preventive HPV vaccines
that target HPV 16 and 18 responsible for causing about 70% of ICC cases in the world, such information is crucial
to predict how vaccination and HPV-based screening will influence prevention of ICC.
Methods: To review the distribution of HPV infection and prevalent genotypes, electronic databases (e.g. PubMed/
MEDLINE and HINARI) were searched for peer reviewed English articles on HPV infection up to November 30, 2010.
Eligible studies were selected according to the following criteria: DNA-confirmed cervical or male genital HPV
prevalence and genotypes, HPV incidence estimates and HPV seroprevalence among participants.
Results: Twenty studies were included in the review. Among HIV negative adult women, the prevalence of HR-HPV
infections ranged from 10.2% -40.0% compared to 37.0% -100.0% among HIV positive women. Among HIV positive
young women aged below 25 years, the prevalence of HR-HPV genotypes ranged from 41.6% -75.0% compared to
23.7% -67.1% among HIV negative women. Multiple infections with non vaccine HR-HPV genotypes were frequent
in both HIV positive and HIV negative women. The main risk factors for prevalent HPV infections were age, lifetime
number of sexual partners and HIV infection. Incident infections with HR-HPV genotypes were more frequent
among adult HIV positive than HIV negative women estimated at 17.3 and 7.0 per 100 person-years, respectively.
Similarly, incident HR-HPV among young women aged below 25 years were more frequent among HIV positive
(40.0 per 100 person-years) than HIV negative women (20.3 per 100 person-years) women. The main risk factor for
incident infection was HIV infection. HPV 16 and 18 were the most common genotypes in ICC with HPV 16/18
contributing up to 73.5% of cases with single infections.
Among uncircumcised adult HIV positive males, HR-HPV prevalence ranged from 55.3% -76.6% compared to 38.6%
-47.6% in HIV negative males. Incident and multiple HR-HPV infections were frequent in HIV positive males. Being
uncircumcised was the main risk factor for both prevalent and incident HPV infection.
Conclusion: Infections with HR-HPV genotypes were very common particularly among HIV positive individuals and
young women irrespective of HIV status. Given the high prevalence of HIV infection, HPV-associated conditions
represent a major public health burden in Uganda. However, although the most common HPV genotypes in ICC
cases in Uganda were those targeted by current preventive vaccines, there were a large number of individuals
infected with other HR-HPV genotypes. Technology allowing, these other HR-HPV types should be considered in
the development of the next generation of vaccines.
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Invasive cervical cancer (ICC) remains a leading cause of
death among women in low-resource settings [1] and
virtually every case of ICC is caused by HPV [2]. Genital
HPV infection is predominantly, but not exclusively, a
sexually transmitted infection and about 50% to 80%
sexually active women are infected by this virus at least
once in their lifetime [3,4]. Worldwide, women in devel-
oping countries account for about 85% of both annual
cases of ICC estimated at 493,000 and annual deaths
from ICC estimated at 273,500 [1]. Men play an impor-
tant role in HPV transmission as HPV DNA has been
detected in the genitalia of up to 73% of healthy men
[5].
Over 100 HPV genotypes have been identified and are
divided into high-risk (HR) and low risk (LR) depending
on their potential to cause cancer. There are about 15
cancer causing HPV genotypes that are responsible for
5% of all human cancers but predominantly cervical
cancer and other anogenital cancers [6]. HPV 16 and
HPV 18 are the most virulent HR-HPV genotypes caus-
ing about 70% of all ICC in the world [7]. Two preven-
tive vaccines targeting HPV 16 and 18 have been
developed and are currently licensed in over 100 coun-
tries including Uganda; Cervarix
®, a bivalent HPV 16/18
from GlaxoSmithKline Biologicals (GSK) and Gardasil
®,
a quadrivalent HPV 6/11/16/18 vaccine from MSD
Merck. Gardasil also targets two LR-HPV genotypes 6
and 11, which together cause 90% of genital warts [8].
These current preventive HPV vaccines however, offer
protection only against a few cancer causing HPV
genotypes.
Uganda has a large burden of ICC. Current estimates
indicate that every year, 3,577 women are diagnosed
with ICC and 2,464 die from the disease. Compared to
the USA, the age adjusted cervical cancer incidence per
100,000 population per yeari s8 . 3t i m e sh i g h e ri n
Uganda (47.5 vs.5.7) and age adjusted death rate as a
result of ICC is 20.5 times higher (34.9 vs. 1.7) [9]. The
high incidence of ICC is a reflection of prevalent HR-
HPV infections and failure to prevent their clinical man-
ifestations by effective screening programs that have
dramatically reduced incidence in developed countries
[10]. The introduction of Cervarix
® by the Program for
Appropriate Technology for Health (PATH) in partner-
ship with the Uganda Ministry of Health may offer the
greatest hope of significant reduction of ICC burden
provided the vaccine is widely and properly delivered
[11]. Furthermore, harmonizing primary (vaccination)
and secondary prevention (screening) will result in
greater reduction of ICC than either program alone [12].
Limited data are however, available on the distribution
of HPV genotypes in the general population and in ICC
in Uganda. Yet, with the advent of HPV vaccination,
such information is crucial for policy makers to predict
how HPV vaccination and HPV-based screening will
influence prevention of ICC. Moreover, even with a suc-
cessful vaccination program, vaccinated women will still
require screening to detect those that will develop ICC
from other HR-HPV genotypes that are not prevented
by current vaccines. Therefore, the objective of this
review was to summarize published data on HPV infec-
tion in Uganda. This review will provide useful baseline
information for evaluating the impact of preventive
HPV vaccines and HPV based technologies used in
screening programs.
Methods
PubMed/MEDLINE and HINARI websites were
searched for peer reviewed English language published
m e d i c a ll i t e r a t u r eo nH P Vi n f e c t i o ni nU g a n d au pt o
November 30, 2010. The search was conducted using
the following medical subject heading (MESH) and text
words either singly or in combination: “HPV”, “geno-
types”,” cervical cancer”, “screening”, “vaccination”, “ser-
ology” and “Uganda”. Eligible studies were selected
according to the following criteria: DNA-confirmed cer-
vical or male genital HPV prevalence, HPV incidence
estimates and HPV seroprevalence among participants.
From each article, information on first author, publica-
tion journal and date, dates of sample collection, HPV
detection methods, study design, anatomical site and
methods of sample collection, population description,
mean or median age of sample with range when avail-
able, sample size, the prevalence of HIV when available,
the prevalence of HPV (overall, high risk, low risk, spe-
cific genotypes) as well as the prevalence of HPV among
HIV positive and HIV negative women. Risk factors for
HPV infection were also extracted when available.
Twenty studies were found and were included in the
review: 9 prevalence studies, 2 prospective cohort stu-
dies in women, 3 randomized controlled trials in men, 4
studies on ICC, and 2 seroprevalence studies.
Methods used for the detection of HPV DNA, typing for
specific genotypes and to determine seroprevalence
Various techniques and assays were used for detection
of HPV DNA and genotyping. Polymerase Chain Reac-
tion™ (PCR) using generic or consensus primers and
Hybrid capture™ 2 (HC2, Digene Co., Gaithersburg,
MD, USA) were used in majority of studies. Both tech-
niques have been optimized to detect 13 HR-HPV geno-
types [13]. However, some studies used the Southern
Blot technique which generally has low sensitivity and
detects only a few HR-HPV genotypes. One HPV sero-
prevalence study was done before the World Health
Organization (WHO) developed international standard
reagents for calibration of HPV DNA assays and kits
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ing results from the different studies as the sensitivities
and specificities of the HPV assays vary widely depend-
ing on the type and quality of the biological specimen
and the type and quality of reagents used. Additionally,
assays differ in their ability to detect different HPV gen-
otypes particularly where there are co-infections with
multiple HPV types [15].
Results
The findings from studies conducted in selected popula-
tions across the country are summarized in Tables 1, 2,
3, 4, 5, 6.
Prevalence of HPV infections in population-and clinic-
based studies of women with and without cervical
abnormalities
In women below 25 years, 71.8% of women who were
positive for HPV 16 and 18 were also infected with
other HR-HPV genotypes [16]. Compared to HIV nega-
tive women, HIV positive women had more HR-HPV
genotypes detected in cervical/vaginal specimens [16-19]
and HSIL lesions [17]. The mean number of HPV geno-
types detected was higher among HIV positive com-
pared to HIV negative women (2.8; range 1-9) and 2.1;
range 1-10, respectively; [t-test, 3.88; p < 0.001]) [16].
Likewise, among young primiparous women, the mean
number of HPV types detected among HIV positive
women was higher (2.4, range 1-10) than among HIV
negative women (1.8, range 1-12) [Student’st - t e s t=
2.79, p = 0.005] [18]. HIV positive women were four
times more likely to have abnormal cytology than HIV
negative women (43% vs. 11.6%, p < 0.001) [19]. HPV
positive women co-infected with HIV had other HR-
HPV genotypes that did not include HPV 16 or 18
[16,17].
Risk factors for prevalent HPV infection
Few studies evaluated risk factors for HPV infections.
Lifetime number of sexual partners [16,20]; HIV positiv-
ity [16,21]; young age at first sexual intercourse [16] and
young age [16,21] were significantly associated with
HPV infection. Relative to women in 19-25 age-group,
the odds of detecting HR-HPV decreased by 48%, 60%,
and 79% among women in 26-30, 31-37, and 38-49 age-
group [21]. On average, the odds of detecting HR-HPV
decreased by 9% for each-year increase in age. However,
HPV was only inversely associated with age (Ptrend
0.001) in HIV negative women as the prevalence of
HPV among HIV positive women seemed to remain
high in all age-groups [20]. Other risk factors found
included: abnormal cytology [17,18]; employment in a
tertiary sector, concurrent pregnancy, presence of geni-
tal warts, and testing positive for Syphilis, Chlamydia
trachomatis and Neisseria Gonnorhea [16]. Smoking
cigarettes the previous year was significantly associated
with HPV infection after controlling for age, age at sex-
ual debut and HIV status (Adjusted OR = 3.74; 95% CI:
1.15-12.16) [21].
HPV 16 and 18 were the most frequent genotypes in
ICC cases. Furthermore, results of pooled data compiled
by the International Agency for Research on Cancer
(IARC) showed a prevalence of HPV 16/18 of 74.1%
(95% CI: 66.4-80.8) [22,23].
Incident and risk factors for HPV infections among
women
HIV positive women were twice as likely to have inci-
dent infection compared to HIV negative women [24].
Risk factors for incident HPV infections were HIV posi-
tivity [24,25]; young age, many lifetime and recent sex-
ual partners and single women [24,25].
Risk factor for HPV infection in males participating in
circumcision trials
Not being circumcised was the main risk factor for both
prevalence and incident HR-HPV infections.
HPV serology
HPV seroprevalence peaked in women below 20 years of
age. The most common HR-HPV serotypes was HPV 33
(23%), HPV 16 (21%), HPV 31 (16%), HPV 45 (11%)
and HPV 18 (8%). The seroprevalence of LR-HPV 6, 11
and HPV 6/11 combined was 30%, 26%, and 44%,
respectively. Of the 1,118 HPV seropositive women, 53%
had antibodies to more than one HPV genotype, 30%
had 2 HPV genotypes, 14% had 3 HPV genotypes and
9% had 4-7 genotypes [26]. Antibodies against HPV 16
were significantly associated with ICC (OR = 2.0; 95%
CI: 1.2-3.1, p < 0.01) [27]. HPV seoprevalence was
higher among HIV positive compared to HIV negative
women, 74.0% and 56%, respectively. Multiple antibody
positivity was more frequent in HIV positive (53%) than
HIV negative women (28%) [26].
Discussion
To the best of our knowledge, this systematic review
represents the first ever to evaluate the burden of HPV
infections and ICC in Uganda. It is worth noting that
comparison of HPV prevalence and incidence rates
across studies was hampered by differences in popula-
tions studied, laboratory methods used, and variation in
HPV genotypes detected. Nevertheless, consistent with
other studies in sub Saharan Africa [28], the review
demonstrated a high burden of HR-HPV genotypes in
the general population and in ICC. HPV 16 and 18 were
the most common genotypes in ICC similar to the glo-
bal HPV distribution pattern [29]. Mathematical models
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Author Area, subjects Study
design
HPV test HPV prevalence for any,
HR*, LR** and specific
genotypes among all
tested women
aor only
HPV positive women
b
HPV prevalence and type
specific genotypes among
among all tested
women
aor only HPV
positive women
b by HIV
status
Comments
Population-Based studies
Serwadda
et al., 1999
[52]
Rakai district, Random sample
of 960 women aged 15-59
years using self collected
vaginal swabs
Cross-
sectional
Hybrid
Capture 2
Any HR-HPV
a, 16.7% HIV status
a
HIV+, 44.3%
HIV-, 10.2%
HIV
prevalence
a,
17.8%
Safaeian
et al., 2007
[53]
Rakai district, 606 women,
median age 30 years (25-38
years)
Baseline of
a
population-
based
cohort
study
Hybrid
Capture 2/
PGMY 09/11
assay
Any HR-HPV
a, 19%
Type-specific genotypes
a
HPV 16, 4.5%
HPV 52, 4.4%
HPV 66, 3.0%
HPV 58, 3.0%
HIV status
a
HIV positive
Self-collected, 40%
Physician collected, 37%
HIV negative
Self-collected, 15%
Physician collected, 16%
HIV
prevalence
a,
15.7%
Asiimwe
et al., 2008
[21]
Bushenyi district, 314 women
with median age of 27 years
(range,18-49) using self
collected vaginal swabs
Cross-
sectional
Hybrid
Capture 2
assay
Any HR-HPV
a, 17.2% HIV
prevalence
a,
5.6% (self-
reported)
Safaeian
et al.,
2008b [20]
Rakai district, 926 sexually
exprienced women aged 15-49
years, mean age 26 years, who
provided at least 3 consecutive
self-collected swabs
Population-
based
cross-
sectional
study
Hybrid
Capture 2/
Prototype
Roche
reverse line
blot assay
Any HR-HPV
a, 19.2%
Type-specific genotypes
a
HPV 52, 2.2%
HPV 16, 2.1%
HPV 51, 1.7%
HPV 66, 1.5%
HPV 68, 1.3%
HIV status
a
HIV+, 46.6%
HIV-, 14.8%
HIV
prevalence
a,
13.7%
Clinic-Based Studies
Adult women
Blossom
et al., 2007
[17]
STI clinic in Kampala, 106
women mean age 26.3 years
(range,18-51)
Cross-
sectional
Roche PCR/
reverse strip
assay
Any HPV
a, 46.2%
Type-specific genotypes
b
HPV 16/18, 18.4%
HPV 52, 14.2%
HPV 16, 7.5%
HPV 58, 7.5%
Any HPV type
a
HIV+, 59.5%
HIV-, 39.1%
HR-HPV types
b
HIV+, 100.0%
HIV-, 88.9%
HIV
prevalence
a,
34.9%
Young women below 25 years
Banura
et al.,
2008a [16]
Clinic for teenagers in Kampala,
1275 sexually active young
women median age 20 years
(range 12-24)
Baseline of
a cohort
study
SPF10/LIPA
PCR assay
Any HPV
a, 74.6%
HR-HPV types
a, 51.4%
Type-specific genotypes
a
HPV 52, 13.2%
HPV 51, 12.3%
HPV 18, 10.7%
HPV 16, 10.6%
LR-HPV types
a, 39.8%
LR-HPV genotypes
a
HPV 6, 15.5%
HPV 11, 13.3%
HIV positive women
Any HPV
a, 87.8%
HR-HPV types, 67.1%
Type-specific genotypes
a
HPV 16, 18.3%
HPV 18, 9.8%
HPV 6, 15.9%
HPV 11, 17.1%
HIV negative women
Any HPV
a, 73.2%
HR-HPV types
a, 49.7%
Type-specific genotypes
a
HPV 16, 10.7%
HPV 18, 12.1%
HPV 6, 15.3%
HPV 11, 12.7%
HIV
prevalence
a,
8.6%
Banura
et al.,
2008b [18]
Antenatal clinic in Kampala
987 young primiparous
pregnant women, median age
19 years (range 14-24)
Baseline of
a cohort
study
SPF10/LIPA
PCR assay
Any HPV
a, 60.0%
High-risk types
b, 43.0%
Type-specific genotypes
b
HPV 52, 12.1%
HPV 51, 8.7%
HPV 16, 8.4%
HPV 18, 5.8%
LR-HPV genotypes
LR-HPV types
b, 23%
Type-specific genotypes
b
HPV 6, 5.5%
HPV 11, 3.2%
HIV positive women
Any HPV
a, 72.2%
Type-specific genotypes
b
HPV 16, 18.1%
HPV 18, 6.9%
HPV 6, 8.3%
HPV 11, 1.4%
HIV negative women
Any HPV
a, 58.9%
Type-specific genotypes
b
HPV 16, 7.7%
HPV 18, 5.7%
HPV 6, 5.3%
HPV 11, 3.4%
HIV
prevalence
a,
7.3%
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containing genotypes 16/18 have the potential to reduce
deaths from ICC by 50% over several decades [30-32].
However, the efficacy of these vaccines in countries like
Uganda with high prevalence of HIV infection, endemic
malnutrition, malaria infection and intestinal worm
infestation is not yet known. Our review also found that
the third most frequent HPV genotype after HPV 16
and 18 among women with ICC was HPV 45, which dif-
fered from the worldwide distribution (HPV 16, 18, 58)
[9]. Variation in HPV genotype distribution in ICC is
not new as it has been observed in other regions of the
world. It is hypothesized that host immunogenetic fac-
tors and biologic interplay between different HPV geno-
t y p e so rv a r i a n t sa r ep r o b a b l yr e s p o n s i b l e[ 3 2 ] .T h i s
variation however, implies that any development of the
next generation of multivalent preventive HPV vaccines
should contain more HR-HPV genotypes than only 16/
18. Based on data contained in this review, multivalent
vaccines containing HPV 16/18/45 would potentially
prevent approximately 83.1% of ICC in Uganda.
The highest prevalence and incidence rates of HPV
infections occurred in young women below 25 years
similar to previous studies [23]. It is important to note
that Ugandan women tend to marry and become sexu-
ally active at a young age and often have older and
more sexually experienced partners, which factors would
put them at greater risk for HPV infection. The main
risk factors for prevalent and incident HPV infections
were age, number of lifetime number of sexual partners
and HIV infection consistent with other studies [23,33].
HIV positive individuals had a high burden of HPV
infection at the time when their life-spans are being pro-
longed by expanded access to highly active anti-retro-
viral therapy (HAART) and medical care. Since 2003,
the HIV prevalence in Uganda has stabilized at about
6.4% among adults and by the end of 2010; approxi-
mately 1.1 million were living with HIV [34]. Women
were disproportionately affected accounting for about
57% of the total adults living with HIV [34]. However,
the proportion of co-infection with HIV and HPV is not
known. Though several studies have consistently shown
a high burden of HPV-associated diseases in HIV posi-
t i v ew o m e ne v e ni nt h ee r ao fH A A R T[ 3 5 ] ,p r e s e n t l y ,
there is limited or noexistent routine screening services
for many HIV positive women. There are advantages to
providing routine screening to HIV positive women. In
Zambia, for example, routine screening prevented one
death from ICC for every 46 HIV positive women
screened [36]. Presently, there is limited data to support
or discourage HPV vaccination of HIV positive indivi-
duals. To date, immune response to HPV vaccination
among HIV positive individuals using the quadrivalent
vaccine is limited to a small study of 120 children aged
7-11 years some of whom used anti retroviral therapy,
which was conducted in the USA [37]. The antibodies
developed by > 99.5% of the vaccinated children were
m u c hl o w e rt h a ni nH I Vn e g a t i v eh i s t o r i c a lc o n t r o l s
Table 1 HPV prevalence and genotype distribution in women with and without cervical abnormalities (Continued)
Screened adult women
Buonaguro
et al., 2000
[54]
Nsambya hospital, Scrapes of 16
women with normal ecto-
cervical epithelium and different
degrees of cervical epithelial
lesions
Cross-
sectional
Southern
Blot analysis
HPV 16
a, 12.5%
Taube
et al., 2010
[19]
Post-natal clinic at Mulago
hospital, Kampala
Cervical exfoliated cells from
196 women, 4-12 weeks post-
partum and aged between 18-
30 years (mean age for HIV -23
± 3; HIV + 25.4 ± 3.2)
Cross-
sectional
Roche Linear
array assay
Any HR-HPV
a, 49.0%
HPV 16/18
a, 24%
HR-HPV types
a
HPV 16, 8.2%
HPV 18, 3.5%
HPV 45, 5.1%
HPV 58, 5.1%
LR-HPV types
a
HPV 6, 2.6%
HPV 11, 1.0%
HIV positive
Any HR-HPV
a, 77.8%
Type-specific genotypes
a
HPV 16, 13.9%
HPV 18, 5.6%
HPV 45, 8.3%
HPV 58, 5.6%
Other HR-HPV, 47.2%
LR-HPV types
HPV 6, 5.6%
HPV 11, 2.8%
HIV negative
Any HR-HPV
a, 42.5%
Type-specific genotypes
b
HPV 16, 6.9%
HPV 18, 3.1%
HPV 45, 4.4%
HPV 58, 5.0%
Other HR-HPV, 30.6%
HIV
prevalence
a,
18.0%
*HR = High Risk; **LR = Low Risk
a Denominator consist of all the tested women
b Denominator consist of only HPV positive women
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and efficacy.
In this review, HIV positive women seemed to have
multiple and more other HR-HPV genotypes than HPV
16/18 consistent with a previous study where 50% of
H I Vp o s i t i v ew o m e nw i t hH P V1 6a n d1 8w e r ec o -
infected with other HR-HPV genotypes [38]. Conse-
quently, it is unclear whether the current vaccines con-
taining only HPV 16 and 18 genotypes may potentially
prevent fewer cases of ICC among HIV positive women
[39]. Fortunately, the current preventive vaccines have
shown cross-protection against some non vaccine HR-
HPV genotypes and because of this, it is estimated that
wide coverage (> 70%) could potentially prevent up to
71% of ICC [40]. Cross-protection even if limited, may
be particularly important in low-resource countries like
Uganda where screening programs are limited or
nonexistent.
Males had a high burden of HR-HPV infections. Stu-
dies have shown that males do not perceive themselves
to be susceptible to HPV and do not believe that HPV
infection is a severe problem to themselves [41]. How-
ever, the role of men as vectors of HR-HPV genotypes
that cause ICC has been extensively evaluated in epide-
miological studies [42-44]. HPV vaccines have been
found to be safe and efficacious in males [45]. However,
vaccinating males does not appear to be economical
when assessed from the view of ICC. Moreover, the
WHO does not recommend routine male vaccination as
the primary target of vaccination. Yet, the concept of
herd immunity in public health would tend to suggest
that vaccinating males would provide a double benefit
to females in that the fewer males with HPV, the fewer
females will be exposed [46].
Although HPV vaccines hold great promise to reduce
ICC-associated mortality and morbidity, it remains
unclear whether low-resource countries like Uganda will
reap the benefits any time soon. The current high cost
of the vaccines, poor health infrastructure and compet-
ing health priorities will prevent young girls getting the
life saving vaccinations. Uganda’s health sector remains
considerably under-funded. At less than 10% of total
Table 2 HPV incidence in women without cervical abnormalities
Author Area, subjects Study
design
HPV
test
HPV incidence rate for any, HR*,
LR** and type-specific
genotypes among all tested
women
a per 100 PYs
HPV incidence for any and
type-specific genotypes all
tested women
a per 100 PYs
by HIV status
Comments
Safaeian
et al.,
2008a
[24]
Rakai district, rural women,
median age 29 years (range,
15-59 years)
Prospective
cohort
HC 2/
PGMY/
09/11
assay
Any HR-HPV
a, 8.7
Type-specific genotypes
a
HPV 16, 1.5
HPV 18, 0.9
HPV 45, 1.1
HPV 51, 1.8
HPV 52, 1.1
HIV Positive
Any HR-HPV
a, 17.3
Type-specific genotypes
a
HPV 16, 3.2
HPV 18, 2.1
HPV 45, 2.7
HPV 51, 5.1
HPV 52, 1.3
HIV Negative
Any HR-HPV
a , 7.0
Type-specific genotypes
a
HPV 16, 1.2
HPV 18, 0.7
HPV 45, 0.8
HPV 51, 1.2
HPV 52, 1.0
HIV
prevalence
a,
14.0%
Banura
et al.,
2010
[25]
Teenage clinic in Kampala,
380 young women, median
age at baseline 19 years
(range, 12-24)
Prospective
cohort
SPF10/
LIPA
PCR
assay
Any HPV
a, 30.5
HR-HPV types, 20.9
LR-HPV types, 10.6
HPV 16-related types, 10.8
HPV 18-related types, 5.6
Type-specific genotypes
HR-HPV genotypes
a
HPV 16, 3.3
HPV 18, 2.0
HPV 45, 1.3
HPV 51, 4.2
HPV 52, 3.4
LR-HPV genotypes
a
HPV 6, 3.4
HPV 11, 1.9
HIV Positive
Any HR-HPV
a, 40.0
Type-specific genotypes
a
HPV 16, 6.7
HPV 18, 3.0
HIV Negative
Any HR-HPV
a, 29.7
Type-specific genotypes
a
HPV 16, 3.0
HPV 18, 2.1
Cumulative
prevalence
over 27.5
months
a
HR-HPV
types, 68.2%
LR-HPV
types, 55.0%
HPV 16-
related
types, 48.6%
HPV 18-
related
types, 28.2%
HR* = High Risk
LR** = Low Risk
a Denominator consist of all the tested women
PYs = Person Years
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health expenditure remains far below the Abuja target
of 15% that the government of Uganda committed to in
2001 [47,48]. Furthermore, presently, there is no known
public sector pricing for the HPV vaccines making it dif-
ficult to budget for and as such the details of vaccine
implementation and cost coverage remain unknown.
Fortunately, the Global Alliance for Vaccines and
Immunization (GAVI) pledged to consider HPV vac-
cines in their investment strategy of 2009-2013 [49].
This may provide the much needed financial help to
implement HPV immunization programs in low-
resource countries where most of the ICC occur.
For prevention, HPV vaccines must be given before
sexual debut to ensure that exposure to HPV has not
occurred. Accordingly, the World Health Organization
recommended that girls between the ages of 9-13 years
should be the primary target of vaccination [50]. Given
the financial impossibility of vaccinating all eligible
women in the reproductive age, it is vital that primary
prevention by HPV vaccination is integrated with
education on risk reducing behaviors and secondary pre-
vention programs via screening and treatment of pre-
cancerous lesions and ICC. The availability of new and
inexpensive screening techniques for rapid identification
of HR-HPV may help facilitate the use of HPV testing
in low-resource countries [51].
Conclusions
HR-HPV infections were frequent in both females and
males. HR-HPV 16 and 18 targeted by the two licensed
preventive HPV vaccines are the most common geno-
types found in ICC cases. However, there are a large
number of individuals infected with other non vaccine
HR-HPV genotypes not targeted by the currently avail-
able HPV vaccine preparations, indicating that these
vaccines could be less effective and leave women at
risk for ICC. Furthermore, given the high prevalence
of HIV infection, HPV-associated conditions represent
a major public health burden in Uganda. Thus, to
further reduce this health burden, any future preven-
tive HPV vaccine(s) should contain more HR-HPV
Table 3 HPV prevalence and genotype distribution among invasive cervical cancer cases
Author Area, subjects Study
design
HPV test HPV prevalence for any and
specific genotypes among all
tested women
a
Comments
Schmauz
et al.,
1989 [55]
Mulago hospital, cervical tissues from 34 cases and 23
controls
Case
Control
Southern
Blot
analysis
Cases
a
HPV 16/18, 50%
HPV 16, 15%
HPV 18, 35%
Controls
a
HPV 18, 4.4%
Prevalence of HIV
a
Cases, 5.9%
Controls, 21.7%
Odds of cervical
cancer
HPV 18 (OR* =
12.0)
HPV16/18 (OR* =
22.0)
Odida
et al.,
2008 [56]
Mulago, Pathology Department 186 paraffin embedded
histologically confirmed archival cervical cancer cases
Collected 1968-69, 1970-79, and 1980-89.
Case
series
SPF10/
LIPA
Any HPV
a, 61.3%
Type-specific genotypes
a
HPV 16/18, 73.5%
HPV 16, 44.7%
HPV 18, 28.8%
HPV 45, 9.6%
Types
146 Squamous cell
carcinoma
35
adenocarcinoma
3 Adenosquamous
2 undifferentiated
types
Odida
et al.,
2010 [57]
Mulago Hospital, Kampala, 171 pairs of paraffin embedded
and freshly frozen tissue samples collected between
September 2004 and December 2006
Case
series
SPF10/
LIPA
Any HPV
a, Frozen tissue, 90.1%
Type-specific genotypes
a
HPV 16, 47.4%
HPV 18, 19.5%
HPV 45, 9.7%
HPV 51, 1.9%
HPV 52, 1.3%
Any HPV
a, Paraffin embedded
tissue, 88.9%
Type-specific genotypes
a
HPV 16, 47.4%
HPV 18, 23.7%
HPV 45, 7.9%
HPV 51, 1.3%
HPV 52, 1.3%
Multiple HPV
genotypes
a
Frozen tissue, 7.1%
Paraffin
embedded, 4.6%
Single HPV
genotypes
a
Frozen tissue,
92.9% (95% CI
†:
87.6-96.4)
Paraffin
embedded, 94.7%
(95% CI
†: 89.9-97.7)
a Denominator consist of all the tested women
CI
† = Confidence Interval
OR* = Odds Ratio
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Page 7 of 12Table 4 HPV prevalence in males participating in circumcision clinical trials
Author Area, subjects Study
design
HPV test HPV prevalence for
HR*, and LR**
genotypes at
enrollment and 24
month follow up in
intervention§ and
control§§
HPV prevalence
for any, HR* and
LR** genotypes
at baseline and
24-month
follow-up
Risk Ratio (RR) and
95% CI† for any, HR*,
LR** and multiple
HPV infections at
baseline and 24-
month follow-up
Tobian
et al.,
2009 [58]
Rakai district, 307 men in
intervention and 233 men
in control group aged 15-49
years who had detectable
beta-globulin or HPV.
Preputal cavity sampled
Randomized
controlled
trial
Roche HPV linear
array. HR-HPV
genotypes 16,
18,31, 33, 35, 39, 45,
51, 52, 56, 58, 59,
66, and 68 tested
At enrollment
HR-HPV genotypes
a
Intervention group,
38.1%
Control group, 37.1%
At 24 months
HR-HPV genotypes
a
Intervention group,
18.0%
Control group, 27.9%
Intervention
Any HPV
genotype
b
Baseline, 61.9%
At 24 months,
35.6%
HR-HPV
genotypes
b
Baseline, 38.1%
At 24 months,
18.0%
LR-HPV genotypes
b
Baseline, 47.6%
At 24 months,
26.2%
Control group
Any HPV types
b
Baseline, 62.6%
At 24 months,
51.2%
HR-HPV
genotypes
b
Baseline, 37.1%
At 24 months,
27.9%
LR-HPV genotypes
b
Baseline, 48.0%
At 24 months,
39.4%
Any HPV genotypes
b
Baseline, 0.99 (0.81-
1.21)
At 24 months, 0.70
(0.53-0.91)
HR-HPV genotypes
b
Baseline, 1.03 (0.79-
1.33)
At 24 months, 0.65
(0.45-0.94)
LR-HPV genotypes
b
Baseline, 0.99 (0.79-
1.25)
At 24 months, 0.66
(0.49-0.91)
Serwadda
et al.,
2010 [59]
Rakai district, uncircumcised
HIV positive men aged 15-
49 years; 103 men in
intervention group and 107
men in control group
Randomized
controlled
trial
Roche HPV linear
array
At enrollment
HR-HPV genotypes
a
Intervention group,
72.2%
Control group, 76.6%
LR-HPV genotypes
a
Intervention group,
85.6%
Control group, 83.0%
At 24 months
HR-HPV genotypes
a
Intervention; 55.3%
Control group; 71.7%
LR-HPV genotypes
a
Intervention group,
49.4%
Control group, 77.4%
At 24 months
RR for HR-HPV geno
types 0.77 (0.62-0.97)
RR for multiple
genotypes 0.53 (0.33-
0.83)
Gray et al.,
2010 [60]
Rakai district, uncircumcised
HIV negative men aged 15-
49 years; 441 randomized to
immediate circumcision
(intervention) and 399
delayed circumcision
(control)
Randomized
controlled
trial
Roche HPV linear
array
At enrollment
HR-HPV genotypes
a
Intervention arm, 39.1%
Control arm, 38.6%
HR* = High Risk
LR** = Low Risk
CI
† = Confidence Intervals
a Denominator include all women tested
b Denominator include only HPV positive women
§ Intervention refers to circumcision arm of the study
§§ Control refers to non circumcision arm of the study
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Page 8 of 12Table 5 HPV incidence in males participating in circumcision clinical trials
Author Area, subjects Study
design
HPV
test
HPV incident cases
c and
rates
d for type-specific
genotypes per 100 PYs
Proportions of type-
specific incident infections
at 24-month follow-up
Risk Ratio (RR)
and 95% CI
†
for HR* and
multiple
infections
Serwadda
et al.,
2010 [59]
Rakai district, uncircumcised HIV
positive men aged 15-49 years;
103 men in intervention group
and 107 men in control group
Randomized
controlled
trial
Roche
HPV
linear
array
At 24 months
HR-HPV incident cases
c
Intervention group, 42
cases
Control group, 57 cases
Multiple infectionincident
cases
c
Intervention group, 9.9
cases
Control group, 24.7 cases
Incident proportions At 24 months
RR for HR-HPV
types = 0.74
(0.54-1.01)
RR for multiple
infection = 0.04
(0.19-0.84).
Intervention
d
(%)
Control
d
(%)
HPV
16
HPV
18
HPV
45
HPV
51
HPV
52
5.8
4.3
4.1
5.4
10.1
14.9
11.1
10.3
13.9
8.2
Gray, et al.
2010 [60]
Rakai district, uncircumcised HIV
negative men aged 15-49 years;
441 men in intervention and 399
men in control group
Randomized
controlled
trial
Roche
HPV
linear
array
At 24 months
HR-HPV incident cases
c
Intervention group, 19.7
cases
Control group, 29.4 cases
Multiple infection incident
cases
c
Intervention group, 6.7
cases
Control group, 14.8 cases
Type specific incidence rates
d
At 24 months
RR for HR-HPV
types = 0.67
(0.51-0.89)
RR for multiple
infections = 0.45
(0.28-0.73)
Intervention Control
Incidence/100 PYs
HPV
16
HPV
18
HPV
45
HPV
51
HPV
52
3.6
1.6
1.6
4.0
1.6
4.8
5.3
2.4
5.3
3.6
HR* = High Risk
CI
† = Confidence Intervals
PYs = Person Years
c Denominator include all women tested
d Denominator include women with HR-HPV
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Page 9 of 12genotypes than only two targeted by the current
vaccines.
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